John Dorfman is chairman of Dorfman Value Investments in Boston, Massachusetts. His firm or clients may own or trade the stocks discussed here. He can be reached at [email protected].
Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable,” suggesting that there could be a shift in fund flows towards different ...
Cantor Fitzgerald has a “Neutral” rating and a $110.00 price objective on the stock. The consensus estimate for Fortinet’s current full-year earnings is $2.05 per share. Get Fortinet alerts: ...
Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for AST SpaceMobile’s current full-year earnings is ($0.40) per share ...
Cantor Fitzgerald upgraded CVS Health (CVS) to Overweight from Neutral. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...
Cantor Fitzgerald upgraded McEwen Mining (MUX) to Buy from Speculative Buy with a $14.50 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top ...
Cantor Fitzgerald raised concerns about the Magnificent Seven stocks, suggesting they may be at risk of losing investor interest as fund flows shift to other sectors. Revenue projections for 2025 are ...
Get Our Latest Research Report on PI Impinj Stock Up 1.4 % Shares of NASDAQ:PI opened at $106.33 on Monday. The stock has a market cap of $3.01 billion, a PE ratio of 78.18 and a beta of 1.88 ...
Wednesday, Western Digital Corp. (NASDAQ:WDC) shares maintained an Overweight rating by analysts at Cantor Fitzgerald, with a steady price target of $95.00. According to InvestingPro data ...
In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Proto Labs (PRLB – Research Report), with a price target of $50.00. The company’s shares closed ...
Cantor Fitzgerald started coverage on shares of Amentum (NYSE:AMTM – Free Report) in a report issued on Friday, Marketbeat.com reports. The brokerage issued a neutral rating and a $25.00 target ...
Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results